EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report

Wei Xie, Yanxue Yin, Jing Wang, Guohui Cui, Lu Zhang

Cancer Reports · 2026-11 · 9 (11)

DOI: 10.1002/cnr2.70733 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly progressive paraparesis, sensory disturbance, urinary retention, B symptoms, and bulky lymphadenopathy. Baseline white blood cell count was 2.30 × 10 9 /L, absolute lymphocyte count 1.48 × 10 9 /L, hemoglobin 82 g/L, platelet count 157 × 10 9 /L, and β2‐microglobulin 8.3 mg/L. CSF flow cytometry identified 46.31% abnormal monoclonal mature small B cells, and IgH/IgK rearrangements were detected. Whole‐spine magnetic resonance imaging showed abnormalities involving the lower medulla oblongata and spinal cord. After dexamethasone and intrathecal chemotherapy, zanubrutinib 160 mg twice daily was initiated in April 2023; venetoclax was started later that month at 20 mg daily and escalated weekly to 400 mg daily. Independent ambulation was restored by Month 3. At Month 4, marrow and CSF cytology/flow cytometry were negative and the largest abdominal mass had decreased from 11.0 × 6.4 to 1.3 × 0.9 cm. Low‐level CSF measurable residual disease (MRD), assessed by flow cytometry through detection of 57 phenotypically abnormal monoclonal mature small B cells (2.22% of nucleated cells), was detected in June 2024 and became negative after lumbar puncture and intrathecal therapy in November 2024. PET/CT in December 2024 showed a Deauville score of 2. Venetoclax was discontinued in April 2025 after approximately 2 years of combination therapy, and zanubrutinib monotherapy was continued. At final follow‐up in April 2026, the patient remained clinically stable with normal bowel and bladder function; marrow and CSF examinations were negative, and brain and whole‐spine MRI showed no intracranial or intraspinal tumor involvement. Blood counts remained generally stable, and no clinically significant toxicity was documented. Conclusion This case supports further investigation of zanubrutinib plus venetoclax as the systemic component of a multimodal treatment strategy for CNS‐involved CLL/SLL. Because corticosteroid and intrathecal therapy were administered concomitantly, and because this is a single case, the independent efficacy and general safety of the oral combination cannot be established.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →